Jesse Boggis, MPH
PhD Student, The Dartmouth Institute for Health Policy & Clinical Practice
Jesse Boggis, MPH is a PhD student at The Dartmouth Institute for Health Policy & Clinical Practice and Center for Technology and Behavioral Health. Jesse came to Dartmouth as a T32 Predoctoral Fellow in the NIDA-funded Science of Co-occurring Disorders training program. In her third year, Jesse was awarded the NIDA-funded Ruth L. Kirschstein National Research Service Award (NRSA) F31 Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research to support her dissertation: Evaluation of a Pharmacist-Integrated Model of Opioid Use Disorder Treatment to Increase Naloxone Co-Prescribing in Primary Care.
Jesse earned her MPH from Boston University School of Public Health with a concentration in community health sciences with mentorship from Dr. Richard Saitz. While at Boston University, she was awarded an internship at the Substance Abuse and Mental Health Services Administration where she analyzed data from the National Survey on Drug Use and Health. Most recently before joining Dartmouth, she managed a NIH-funded multi-site randomized clinical trial aimed to enhance access to naloxone, syringes, and buprenorphine.
At Dartmouth she is mentored by Dr. Lisa Marsch and contributes towards The Northeast Node of the National Drug Abuse Treatment Clinical Trials Network. She is interested in using mixed methods approaches to examine substance use, access to medication treatment for opioid use disorder, and evidence-based models of care which integrate harm reduction to reduce overdose mortality. Outside of the office, Jesse volunteers at the local syringe service program. In her free time, she also enjoys going on walks in the woods with her dog, playing tennis, skiing, and traveling.
Selected Publications
- Irwin AN, Gray M, Ventricelli D, Boggis JS, Bratberg J, Floyd AS, Silcox J, Hartung DM, Green TC. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials. Res Social Adm Pharm. 2024 May;20(5):512-519. doi: 10.1016/j.sapharm.2024.02.001. PMID: 38395644; PMCID: PMC10981567.
- Irvine MA, Oller D, Boggis J, Bishop B, Coombs D, Wheeler E, Doe-Simkins M, Walley AY, Marshall BDL, Bratberg J, Green TC. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: A modelling study. Lancet Public Health. 2022 Mar;7(3):e210-e218. doi: 10.1016/S2468-2667(21)00304-2. PMID: 35151372.
- Boggis JS, Feder K. Trends in and correlates of tranquilizer misuse among adults who misuse opioids in the United States, 2002-2014. Drug Alcohol Depend. 2019 May 1;198:158-161. doi: 10.1016/j.drugalcdep.2019.01.014. PMID: 30928886.